Google
×
AllImagesBooksNews Maps Videos Shopping
Search tools
Archives
  • Recent
  • Past hour
  • Past 24 hours
  • Past week
  • Past month
  • Past year
  • Archives
Sorted by relevance
Clear

Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers

The New England Journal of Medicine
In recipients of allogeneic hematopoietic-cell transplants, peripheral-blood cells mobilized with the use of filgrastim (recombinant...
287 months ago

Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation

Frontiers
Over the last decade, the development of multiple strategies to allow the safe transfer from the donor to the patient of high numbers of partially...
11 months ago

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P578) | Bone Marrow Transplantation

Nature
This study estimated the cost-effectiveness of axi-cel versus SoC from a third-party US payer perspective in the 2L setting.
26 months ago

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Cancer Network
Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been...
4 months ago

Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation

The New England Journal of Medicine
After transplantation of haploidentical hematopoietic stem cells and infusion of donor T cells, leukemic cells can escape from the donor's antileukemic T cells.
81 months ago

Kinetics of disappearance and appearance of isoagglutinins A and B after ABO-incompatible hematopoietic stem cell transplantation

Nature
ABO-incompatible allogeneic hematopoietic stem cell transplantation (HSCT) can be complicated by poor red cell engraftment and hemolysis,...
30 months ago

Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation

Frontiers
In this review, we discuss recipient risk assessment for allo-HCT regarding comorbidities present at baseline to predict non relapse mortality.
17 months ago

BMT for Myelodysplastic Syndrome: When and Where and How

Frontiers
<sup>1</sup>Fellow, Hematology Oncology, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, United States; <sup>2</sup>Department of Blood and Marrow Transplant and...
18 months ago

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Nature
These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer...
16 months ago

Improving the safety of cell therapy with the TK-suicide gene

Frontiers
While opening new frontiers for the cure of malignant and non-malignant diseases, the increasing use of cell therapy poses also several new...
116 months ago